Efsevia Vakiani

17.2k total citations · 1 hit paper
115 papers, 4.5k citations indexed

About

Efsevia Vakiani is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research. According to data from OpenAlex, Efsevia Vakiani has authored 115 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Oncology, 50 papers in Pathology and Forensic Medicine and 29 papers in Cancer Research. Recurrent topics in Efsevia Vakiani's work include Colorectal Cancer Treatments and Studies (41 papers), Genetic factors in colorectal cancer (39 papers) and Cancer Genomics and Diagnostics (25 papers). Efsevia Vakiani is often cited by papers focused on Colorectal Cancer Treatments and Studies (41 papers), Genetic factors in colorectal cancer (39 papers) and Cancer Genomics and Diagnostics (25 papers). Efsevia Vakiani collaborates with scholars based in United States, Japan and Canada. Efsevia Vakiani's co-authors include David B. Solit, Jinru Shia, Nancy E. Kemeny, Martin R. Weiser, David S. Klimstra, Leonard B. Saltz, Andrea Cercek, Rona Yaeger, Marinela Capanu and Michael F. Berger and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Efsevia Vakiani

109 papers receiving 4.4k citations

Hit Papers

Small Cell and Large Cell Neuroendocrine Carcinomas of th... 2012 2026 2016 2021 2012 100 200 300

Peers

Efsevia Vakiani
Chang‐Ok Suh South Korea
Mark J. Routbort United States
Chang Ohk Sung South Korea
Jaclyn F. Hechtman United States
Michael N. Needle United States
Chang‐Ok Suh South Korea
Efsevia Vakiani
Citations per year, relative to Efsevia Vakiani Efsevia Vakiani (= 1×) peers Chang‐Ok Suh

Countries citing papers authored by Efsevia Vakiani

Since Specialization
Citations

This map shows the geographic impact of Efsevia Vakiani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Efsevia Vakiani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Efsevia Vakiani more than expected).

Fields of papers citing papers by Efsevia Vakiani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Efsevia Vakiani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Efsevia Vakiani. The network helps show where Efsevia Vakiani may publish in the future.

Co-authorship network of co-authors of Efsevia Vakiani

This figure shows the co-authorship network connecting the top 25 collaborators of Efsevia Vakiani. A scholar is included among the top collaborators of Efsevia Vakiani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Efsevia Vakiani. Efsevia Vakiani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shia, Jinru, Francisco Sánchez-Vega, Jie‐Fu Chen, et al.. (2024). MSH6-proficient crypt foci in MSH6 constitutional mismatch repair deficiency: reversion of a frameshifted coding microsatellite to its wild-type sequence. Familial Cancer. 23(4). 569–577.
2.
Ecker, Brett L., Quisette P. Janssen, Henry Walch, et al.. (2023). Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research. 29(7). 1368–1374. 13 indexed citations
3.
Foote, Michael B., Henry Walch, Yelena Kemel, et al.. (2023). The Impact of Germline Alterations in Appendiceal Adenocarcinoma. Clinical Cancer Research. 29(14). 2631–2637. 2 indexed citations
4.
Yoshida, Masao, Hirotsugu Sakamoto, А. А. Теплов, et al.. (2022). Pathological Evaluation of Rectal Cancer Specimens Using Micro-Computed Tomography. Diagnostics. 12(4). 984–984. 3 indexed citations
5.
Deborde, Sylvie, Ann Powers, Andrea Marcadis, et al.. (2022). Reprogrammed Schwann Cells Organize into Dynamic Tracks that Promote Pancreatic Cancer Invasion. Cancer Discovery. 12(10). 2454–2473. 82 indexed citations
6.
Vakiani, Efsevia, Mithat Gönen, Nancy E. Kemeny, et al.. (2022). Biopsy and Margins Optimize Outcomes after Thermal Ablation of Colorectal Liver Metastases. Cancers. 14(3). 693–693. 21 indexed citations
7.
Chakraborty, Saptarshi, Brett L. Ecker, Kenneth Seier, et al.. (2021). Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care. Clinical Cancer Research. 27(21). 5891–5899. 12 indexed citations
8.
Jolissaint, Joshua S., Kevin C. Soares, Kenneth Seier, et al.. (2021). Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection. Clinical Cancer Research. 27(14). 4101–4108. 30 indexed citations
9.
Vakiani, Efsevia, Sho Fujisawa, Mithat Gönen, et al.. (2021). Immunofluorescence Assay of Ablated Colorectal Liver Metastases: The Frozen Section of Image-Guided Tumor Ablation?. Journal of Vascular and Interventional Radiology. 33(3). 308–315.e1. 5 indexed citations
10.
Chernichenko, Natalya, Tatiana Omelchenko, Sylvie Deborde, et al.. (2020). Cdc42 Mediates Cancer Cell Chemotaxis in Perineural Invasion. Molecular Cancer Research. 18(6). 913–925. 21 indexed citations
11.
Wang, Tao, Esther Drill, Efsevia Vakiani, et al.. (2019). Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma. Human Pathology. 91. 19–25. 12 indexed citations
12.
Yaeger, Rona, Zhan Yao, David M. Hyman, et al.. (2017). Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer Research. 77(23). 6513–6523. 60 indexed citations
13.
Lee, Lik Hang, Rhonda K. Yantiss, Eran Sadot, et al.. (2016). Diagnosing colorectal medullary carcinoma: interobserver variability and clinicopathological implications. Human Pathology. 62. 74–82. 16 indexed citations
14.
Hechtman, Jaclyn F., Ahmet Zehir, Rona Yaeger, et al.. (2015). Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. Molecular Cancer Research. 14(3). 296–301. 43 indexed citations
15.
Yaeger, Rona, Andrea Cercek, Eileen M. O’Reilly, et al.. (2015). Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF -Mutant Metastatic Colorectal Cancer Patients. Clinical Cancer Research. 21(6). 1313–1320. 221 indexed citations
16.
Hechtman, Jaclyn F., Weiguo Liu, Justyna Sadowska, et al.. (2015). Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). Modern Pathology. 28(8). 1123–1129. 49 indexed citations
17.
Shia, Jinru, Zsofia K. Stadler, Martin R. Weiser, et al.. (2014). Mismatch repair deficient-crypts in non-neoplastic colonic mucosa in Lynch syndrome: insights from an illustrative case. Familial Cancer. 14(1). 61–68. 24 indexed citations
18.
Wang, Yufang, Sérgia Velho, Efsevia Vakiani, et al.. (2012). Mutant N-RAS Protects Colorectal Cancer Cells from Stress-Induced Apoptosis and Contributes to Cancer Development and Progression. Cancer Discovery. 3(3). 294–307. 42 indexed citations
19.
Saltz, Leonard B., Suprith Badarinath, Shaker R. Dakhil, et al.. (2011). Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer. Clinical Colorectal Cancer. 11(2). 101–111. 58 indexed citations
20.
Vakiani, Efsevia, et al.. (2007). Hepatitis C–Associated Granulomas After Liver Transplantation. American Journal of Clinical Pathology. 127(1). 128–134. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026